We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amphastar Pharmaceuticals Inc | NASDAQ:AMPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.47% | 42.46 | 42.00 | 44.89 | 43.1286 | 42.03 | 42.99 | 353,239 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Zhang Jack Y. |
2. Issuer Name
and
Ticker or Trading Symbol
Amphastar Pharmaceuticals, Inc. [ AMPH ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director __ X __ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) CEO & Chief Scientific Officer |
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
RANCHO CUCAMONGA, CA 91730 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 3/15/2019 | M | 514783 | A | $15.84 | 2587100 | D | |||
Common Stock | 3/15/2019 | F | 461097 (1) | D | $20.23 | 2126003 | D | |||
Common Stock | 3/15/2019 | A | 98368 (2) | A | $0 | 2224371 | D | |||
Common Stock | 3/15/2019 | F | 17205 (3) | D | $20.23 | 2207166 | D | |||
Common Stock | 3/16/2019 | F | 27476 (3) | D | $20.23 | 2179690 | D | |||
Common Stock | 3/17/2019 | F | 32374 (3) | D | $20.23 | 2147316 | D | |||
Common Stock | 3/15/2019 | M | 224737 | A | $15.84 | 1591443 | I | See footnote (4) | ||
Common Stock | 3/15/2019 | F | 200853 (1) | D | $20.23 | 1390590 | I | See footnote (4) | ||
Common Stock | 3/15/2019 | A | 41522 (2) | A | $0 | 1432112 | I | See footnote (4) | ||
Common Stock | 3/15/2019 | F | 7317 (3) | D | $20.23 | 1424795 | I | See footnote (4) | ||
Common Stock | 3/16/2019 | F | 11832 (3) | D | $20.23 | 1412963 | I | See footnote (4) | ||
Common Stock | 3/17/2019 | F | 13941 (3) | D | $20.23 | 1399022 | I | See footnote (4) | ||
Common Stock | 7327679 | I | See footnote (5) | |||||||
Common Stock | 5000 | I | See footnote (6) | |||||||
Common Stock | 200000 | I | See footnote (7) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Employee Stock Option (right to buy) | $15.84 | 3/15/2019 | M | 514783 | (8) | 3/27/2019 | Common Stock | 0 | $0 | 0 | D | ||||
Employee Stock Option (right to buy) | $22.25 | 3/15/2019 | A | 262182 | (9) | 3/15/2027 | Common Stock | 262182 | $0 | 262182 | D | ||||
Employee Stock Option (right to buy) | $15.84 | 3/15/2019 | M | 224737 | (8) | 3/27/2019 | Common Stock | 0 | $0 | 0 | I | See footnote (4) | |||
Employee Stock Option (right to buy) | $22.25 | 3/15/2019 | A | 110671 | (9) | 3/15/2027 | Common Stock | 110671 | $0 | 110671 | I | See footnote (4) |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Zhang Jack Y.
C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730 |
X | X | CEO & Chief Scientific Officer |
|
|
Luo Mary Z.
C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730 |
X | X | COO Chief Scientist & Chairman |
|
Signatures
|
||
/s/ Eva Wen, by power of attorney for Jack Y. Zhang | 3/18/2019 | |
** Signature of Reporting Person |
Date
|
|
/s/ Eva Wen, by power of attorney for Mary Z. Luo | 3/18/2019 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Amphastar Pharmaceuticals Chart |
1 Month Amphastar Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions